Skip to main content
Journal cover image

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.

Publication ,  Journal Article
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group,
Published in: Lancet Infect Dis
May 2022

BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. METHODS: In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. FINDINGS: Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50-72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74-1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67-1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74-1·58]; BRII-196 plus BRII-198 1·00 [0·68-1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91-1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88-1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. INTERPRETATION: Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. FUNDING: US National Institutes of Health and Operation Warp Speed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet Infect Dis

DOI

EISSN

1474-4457

Publication Date

May 2022

Volume

22

Issue

5

Start / End Page

622 / 635

Location

United States

Related Subject Headings

  • Treatment Outcome
  • SARS-CoV-2
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • COVID-19 Drug Treatment
  • Antibodies, Neutralizing
 

Citation

APA
Chicago
ICMJE
MLA
NLM
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, . (2022). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis, 22(5), 622–635. https://doi.org/10.1016/S1473-3099(21)00751-9
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Morris. “Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.Lancet Infect Dis 22, no. 5 (May 2022): 622–35. https://doi.org/10.1016/S1473-3099(21)00751-9.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Morris. “Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.Lancet Infect Dis, vol. 22, no. 5, May 2022, pp. 622–35. Pubmed, doi:10.1016/S1473-3099(21)00751-9.
Journal cover image

Published In

Lancet Infect Dis

DOI

EISSN

1474-4457

Publication Date

May 2022

Volume

22

Issue

5

Start / End Page

622 / 635

Location

United States

Related Subject Headings

  • Treatment Outcome
  • SARS-CoV-2
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • Female
  • Double-Blind Method
  • COVID-19 Drug Treatment
  • Antibodies, Neutralizing